Oncology Department, Centre Jean Perrin, Clermont-Ferrand F-63011, France.
Cancer Treat Rev. 2013 Apr;39(2):125-35. doi: 10.1016/j.ctrv.2012.06.002. Epub 2012 Jul 19.
Temozolomide (TMZ) was first known to be useful as a radiosensitiser in both primary brain tumours like glioblastoma multiforme and oligodendroglioma. Later, TMZ proved its efficacy in the treatment of melanoma. Multiple publications have demonstrated the benefit of TMZ in terms of efficacy and tolerance (used as mono-therapy or as adjuvant chemotherapy) compared to the "gold standard" treatment of this kind of tumours. Furthermore, several recent clinical trials have shown the particular importance of TMZ in other types of cancer. This publication deals with the use of TMZ in cancers which are not formal indications for TMZ (excluding glioblastoma multiforme, oligodendroglioma and melanoma). It also includes a necessary review of recent literature about the role of TMZ in the treatment of brain metastases, lymphomas, refractory leukaemia, neuroendocrine tumours, pituitary tumours, Ewing's sarcoma, primitive neuroectodermal tumours, lung cancer and other tumours.
替莫唑胺 (TMZ) 最初被认为是一种有效的放射增敏剂，可用于治疗多种原发性脑肿瘤，如多形性胶质母细胞瘤和少突胶质细胞瘤。后来，TMZ 被证明在治疗黑色素瘤方面具有疗效。多项研究结果表明，TMZ 在疗效和耐受性方面（单独使用或作为辅助化疗）优于此类肿瘤的“金标准”治疗。此外，最近的几项临床试验表明 TMZ 在其他类型癌症中的重要作用。本文主要讨论了 TMZ 在非 TMZ 适应证癌症中的应用（不包括多形性胶质母细胞瘤、少突胶质细胞瘤和黑色素瘤）。本文还对 TMZ 在脑转移瘤、淋巴瘤、难治性白血病、神经内分泌肿瘤、垂体瘤、尤文肉瘤、原始神经外胚层肿瘤、肺癌和其他肿瘤治疗中的作用进行了必要的文献回顾。
